Taverniti, V.; Ligat, G.; Debing, Y.; Kum, D.B.; Baumert, T.F.; Verrier, E.R.
Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives. J. Clin. Med. 2022, 11, 1349.
https://doi.org/10.3390/jcm11051349
AMA Style
Taverniti V, Ligat G, Debing Y, Kum DB, Baumert TF, Verrier ER.
Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives. Journal of Clinical Medicine. 2022; 11(5):1349.
https://doi.org/10.3390/jcm11051349
Chicago/Turabian Style
Taverniti, Valerio, Gaëtan Ligat, Yannick Debing, Dieudonne Buh Kum, Thomas F. Baumert, and Eloi R. Verrier.
2022. "Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives" Journal of Clinical Medicine 11, no. 5: 1349.
https://doi.org/10.3390/jcm11051349
APA Style
Taverniti, V., Ligat, G., Debing, Y., Kum, D. B., Baumert, T. F., & Verrier, E. R.
(2022). Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives. Journal of Clinical Medicine, 11(5), 1349.
https://doi.org/10.3390/jcm11051349